Key facts for NCD 190.17
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 11/25/2002
- Implemented 01/01/2003
- Transmittal
- Transmittal 17
- Versions published
- 1
- Lab edit list
- 7,273 covered ICD-10
- 233 non-covered
TL;DR
NCD 190.17 sets Medicare's national policy for prothrombin time (pt) under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • A PT may be used to assess patients taking warfarin. The prothrombin time is generally not useful in monitoring patients receiving heparin who are not taking warfarin. As a laboratory NCD it carries a national ICD-10 edit list: 7,273 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.
Item or service described
Basic plasma coagulation function is readily assessed with a few simple laboratory tests: the partial thromboplastin time (PTT), PT, thrombin time (TT), or a quantitative fibrinogen determination. The PT test is one in-vitro laboratory test used to assess coagulation. While the PTT assesses the intrinsic limb of the coagulation system, the PT assesses the extrinsic or tissue factor dependent pathway. Both tests also evaluate the common coagulation pathway involving all the reactions that occur after the activation of factor X.
Extrinsic pathway factors are produced in the liver and their production is dependent on adequate vitamin K activity. Deficiencies of factors may be related to decreased production or increased consumption of coagulation factors. The PT/INR is most commonly used to measure the effect of warfarin and regulate its dosing. Warfarin blocks the effect of vitamin K on hepatic production of extrinsic pathway factors.
A PT is expressed in seconds and/or as an international normalized ratio (INR). The INR is the PT ratio that would result if the WHO reference thromboplastin had been used in performing the test.
Current medical information does not clarify the role of laboratory PT testing in patients who are self monitoring. Therefore, the indications for testing apply regardless of whether or not the patient is also PT self-testing.
Indications and limitations of coverage
Indications
• A PT may be used to assess patients taking warfarin. The prothrombin time is generally not useful in monitoring patients receiving heparin who are not taking warfarin.
• A PT may be used to assess patients with signs or symptoms of abnormal bleeding or thrombosis. For example: swollen extremity with or without prior trauma; unexplained bruising; abnormal bleeding, hemorrhage or hematoma; petechiae or other signs of thrombocytopenia that could be due to disseminated intravascular coagulation.
• A PT may be useful in evaluating patients who have a history of a condition known to be associated with the risk of bleeding or thrombosis that is related to the extrinsic coagulation pathway. Such abnormalities may be genetic or acquired. For example: dysfibrinogenemia; afibrinogenemia (complete); acute or chronic liver dysfunction or failure, including Wilson's disease and Hemochromatosis; disseminated intravascular coagulation (DIC); congenital and acquired deficiencies of factors II, V, VII, X; vitamin K deficiency; lupus erythematosus; hypercoagulable state; paraproteinemia; lymphoma; amyloidosis; acute and chronic leukemias; plasma cell dyscrasia; HIV infection; malignant neoplasms; hemorrhagic fever; salicylate poisoning; obstructive jaundice; intestinal fistula; malabsorption syndrome; colitis; chronic diarrhea; presence of peripheral venous or arterial thrombosis or pulmonary emboli or myocardial infarction; patients with bleeding or clotting tendencies; organ transplantation; presence of circulating coagulation inhibitors.
• A PT may be used to assess the risk of hemorrhage or thrombosis in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis. For example: evaluation prior to invasive procedures or operations of patients with personal history of bleeding or a condition associated with coagulopathy prior to the use of thrombolytic medication.
Limitations
• When an ESRD patient is tested for PT, testing more frequently than weekly requires documentation of medical necessity, e.g., other than chronic renal failure or renal failure, unspecified.
• The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of warfarin. In a patient on stable warfarin therapy, it is ordinarily not necessary to repeat testing more than every two to three weeks. When testing is performed to evaluate a patient with signs or symptoms of abnormal bleeding or thrombosis and the initial test result is normal, it is ordinarily not necessary to repeat testing unless there is a change in the patient's medical status.
• Since the INR is a calculation, it will not be paid in addition to the PT when expressed in seconds, and is considered part of the conventional PT test.
• Testing prior to any medical intervention associated with a risk of bleeding and thrombosis (other than thrombolytic therapy) will generally be considered medically necessary only where there are signs or symptoms of a bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis or a condition associated with a coagulopathy. Hospital/clinic-specific policies, protocols, etc., in and of themselves, cannot alone justify coverage.
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.17 version 1. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 7,273 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.
1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 85610 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $4.29, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 85610 | $4.29 | $4.29 | national payment amount |
The first 40 of 7,273 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.
| ICD-10-CM | Description | Effective |
|---|---|---|
| A01.00 | Typhoid fever, unspecified | 2015-10-01 |
| A01.01 | Typhoid meningitis | 2015-10-01 |
| A01.02 | Typhoid fever with heart involvement | 2015-10-01 |
| A01.03 | Typhoid pneumonia | 2015-10-01 |
| A01.04 | Typhoid arthritis | 2015-10-01 |
| A01.05 | Typhoid osteomyelitis | 2015-10-01 |
| A01.09 | Typhoid fever with other complications | 2015-10-01 |
| A01.1 | Paratyphoid fever A | 2015-10-01 |
| A01.2 | Paratyphoid fever B | 2015-10-01 |
| A01.3 | Paratyphoid fever C | 2015-10-01 |
| A01.4 | Paratyphoid fever, unspecified | 2015-10-01 |
| A02.0 | Salmonella enteritis | 2015-10-01 |
| A02.1 | Salmonella sepsis | 2015-10-01 |
| A02.20 | Localized salmonella infection, unspecified | 2015-10-01 |
| A02.21 | Salmonella meningitis | 2015-10-01 |
| A02.22 | Salmonella pneumonia | 2015-10-01 |
| A02.23 | Salmonella arthritis | 2015-10-01 |
| A02.24 | Salmonella osteomyelitis | 2015-10-01 |
| A02.25 | Salmonella pyelonephritis | 2015-10-01 |
| A02.29 | Salmonella with other localized infection | 2015-10-01 |
| A02.8 | Other specified salmonella infections | 2015-10-01 |
| A02.9 | Salmonella infection, unspecified | 2015-10-01 |
| A18.84 | Tuberculosis of heart | 2015-10-01 |
| A41.9 | Sepsis, unspecified organism | 2015-10-01 |
| A91 | Dengue hemorrhagic fever | 2015-10-01 |
| A92.0 | Chikungunya virus disease | 2015-10-01 |
| A95.0 | Sylvatic yellow fever | 2015-10-01 |
| A95.1 | Urban yellow fever | 2015-10-01 |
| A95.9 | Yellow fever, unspecified | 2015-10-01 |
| A96.0 | Junin hemorrhagic fever | 2015-10-01 |
| A96.1 | Machupo hemorrhagic fever | 2015-10-01 |
| A96.8 | Other arenaviral hemorrhagic fevers | 2015-10-01 |
| A96.9 | Arenaviral hemorrhagic fever, unspecified | 2015-10-01 |
| A98.0 | Crimean-Congo hemorrhagic fever | 2015-10-01 |
| A98.1 | Omsk hemorrhagic fever | 2015-10-01 |
| A98.2 | Kyasanur Forest disease | 2015-10-01 |
| A98.5 | Hemorrhagic fever with renal syndrome | 2015-10-01 |
| A98.8 | Other specified viral hemorrhagic fevers | 2015-10-01 |
| A99 | Unspecified viral hemorrhagic fever | 2015-10-01 |
| B15.0 | Hepatitis A with hepatic coma | 2015-10-01 |
233 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 10 codes added and 8 codes removed against January 2026. CMS marked 10 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.
| ICD-10-CM | FY2027 description | Result |
|---|---|---|
| D69.11 | Glanzmann thrombasthenia | covered |
| D69.19 | Other qualitative platelet defects | covered |
| I42.00 | Dilated cardiomyopathy, unspecified | covered |
| I42.01 | Familial-genetic dilated cardiomyopathy | covered |
| I42.09 | Other dilated cardiomyopathy | covered |
| I42.81 | Arrhythmogenic cardiomyopathy | covered |
| I42.89 | Other cardiomyopathies not elsewhere classified | covered |
| I49.81 | Brugada syndrome | covered |
| I49.82 | Ventricular bigeminy | covered |
| I49.89 | Other specified cardiac arrhythmias not elsewhere classified | covered |
| ICD-10-CM | Description | Was | Why |
|---|---|---|---|
| D69.1 | Qualitative platelet defects | covered | deleted from ICD-10-CM; replaced by D69.11, D69.19 |
| I42.0 | Dilated cardiomyopathy | covered | deleted from ICD-10-CM; replaced by I42.00, I42.01, I42.09 |
| I42.8 | Other cardiomyopathies | covered | deleted from ICD-10-CM; replaced by I42.81, I42.89 |
| I49.8 | Other specified cardiac arrhythmias | covered | deleted from ICD-10-CM; replaced by G90.A, I49.81, I49.82, I49.89 |
| T52.8X1A | Toxic effect of other organic solvents, accidental (unintentional), initial encounter | covered | deleted from ICD-10-CM; replaced by T52.811A, T52.821A, T52.891A |
| T52.8X2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter | covered | deleted from ICD-10-CM; replaced by T52.812A, T52.822A, T52.892A |
| T52.8X3A | Toxic effect of other organic solvents, assault, initial encounter | covered | deleted from ICD-10-CM; replaced by T52.813A, T52.823A, T52.893A |
| T52.8X4A | Toxic effect of other organic solvents, undetermined, initial encounter | covered | deleted from ICD-10-CM; replaced by T52.814A, T52.824A, T52.894A |
Codes on this NCD's list by release: October 2025: 7,469 · January 2026: 7,504 · October 2026: 7,506. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Revision history
07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.17
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.17
What does NCD 190.17 cover?
• A PT may be used to assess patients taking warfarin. The prothrombin time is generally not useful in monitoring patients receiving heparin who are not taking warfarin. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.17 take effect?
The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.
Does a Local Coverage Determination override NCD 190.17?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.17?
The October 2026 laboratory NCD edit list contains 7,273 ICD-10-CM codes that support prothrombin time (pt) (for example A01.00 Typhoid fever, unspecified; A01.01 Typhoid meningitis; A01.02 Typhoid fever with heart involvement) and 233 codes that deny. The list applies to 85610.
How often does the lab NCD code list for 190.17 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.